DE602005010844D1 - Pharmazeutische zusammensetzungen mit interferon-tau - Google Patents
Pharmazeutische zusammensetzungen mit interferon-tauInfo
- Publication number
- DE602005010844D1 DE602005010844D1 DE602005010844T DE602005010844T DE602005010844D1 DE 602005010844 D1 DE602005010844 D1 DE 602005010844D1 DE 602005010844 T DE602005010844 T DE 602005010844T DE 602005010844 T DE602005010844 T DE 602005010844T DE 602005010844 D1 DE602005010844 D1 DE 602005010844D1
- Authority
- DE
- Germany
- Prior art keywords
- pharmaceutical compositions
- interferon tau
- mammal
- interleukin
- method includes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/06—Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Virology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Zoology (AREA)
- Physical Education & Sports Medicine (AREA)
- Molecular Biology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Wood Science & Technology (AREA)
- Ophthalmology & Optometry (AREA)
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US55227904P | 2004-03-10 | 2004-03-10 | |
US10/825,457 US20050118138A1 (en) | 2000-07-19 | 2004-04-14 | Method of treatment using interferon-tau |
US10/824,710 US7083782B2 (en) | 2000-07-19 | 2004-04-14 | Method of treatment using interferon-tau |
US10/825,382 US20050118137A1 (en) | 2000-07-19 | 2004-04-14 | Method of treatment using interferon-tau |
US10/825,068 US20040247565A1 (en) | 2000-07-19 | 2004-04-14 | Method of treatment using interferon-tau |
US10/884,741 US20050084478A1 (en) | 2000-10-17 | 2004-07-02 | Combination therapy using interferon-tau |
US11/040,706 US20050226845A1 (en) | 2004-03-10 | 2005-01-21 | Method of treatment using interferon-tau |
PCT/US2005/007887 WO2005087254A2 (en) | 2004-03-10 | 2005-03-09 | Pharmaceutical compositions comprising interferon-tau |
Publications (1)
Publication Number | Publication Date |
---|---|
DE602005010844D1 true DE602005010844D1 (de) | 2008-12-18 |
Family
ID=39967097
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE602005010844T Active DE602005010844D1 (de) | 2004-03-10 | 2005-03-09 | Pharmazeutische zusammensetzungen mit interferon-tau |
Country Status (9)
Country | Link |
---|---|
US (1) | US20050226845A1 (de) |
EP (2) | EP1740201B1 (de) |
JP (2) | JP2007528407A (de) |
KR (2) | KR20070004781A (de) |
AT (1) | ATE413187T1 (de) |
AU (2) | AU2005221682A1 (de) |
CA (2) | CA2558803A1 (de) |
DE (1) | DE602005010844D1 (de) |
WO (2) | WO2005087254A2 (de) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7431920B2 (en) | 2000-07-19 | 2008-10-07 | Pepgen Corporation | Method of treating IL-10 deficiency |
US20090246170A1 (en) * | 2006-05-31 | 2009-10-01 | Dnavec Corporation | Therapeutic Agent For Alzheimer's Disease |
WO2009002867A2 (en) * | 2007-06-26 | 2008-12-31 | Nutrition 21, Inc. | Multiple unit dosage form having a therapeutic agents in combination with a nutritional supplement |
WO2011049825A1 (en) | 2009-10-22 | 2011-04-28 | Gilead Sciences, Inc. | Derivatives of purine or deazapurine useful for the treatment of (inter alia) viral infections |
JP5793188B2 (ja) * | 2011-05-13 | 2015-10-14 | 国立大学法人 東京大学 | 自己免疫疾患治療及び予防薬としてのctrp6 |
BR112018076437A2 (pt) * | 2016-06-20 | 2019-10-01 | Ambrx Inc | interferon porcino peguilado e seus métodos de utilização |
JP2020528413A (ja) * | 2017-07-21 | 2020-09-24 | ヴィーブ ヘルスケア カンパニー | Hiv感染症及びaidsを治療するためのレジメン |
Family Cites Families (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4769235A (en) * | 1984-01-27 | 1988-09-06 | New York University | Immunodominant epitope of the circumsporozoite surface protein |
US4766068A (en) * | 1984-06-16 | 1988-08-23 | Agency Of Industrial Science And Technology | Cytochrome P-450MC gene, expression plasmid carrying the said gene, yeasts transformed with the said plasmid and a process for producing cytochrome P-450MC by culturing the said transformant yeasts |
USH22H (en) * | 1984-10-22 | 1986-02-04 | Cetus Corporation | Synergistic effect of chemotherapeutic agents on beta-interferon |
US4683202A (en) * | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US4683195A (en) * | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US4822605A (en) * | 1986-02-18 | 1989-04-18 | Exovir, Inc. | Compositions and methods employing the same for the treatment of viral and cancerous skin lesions and the like |
US5098702A (en) * | 1986-04-09 | 1992-03-24 | Cetus Corporation | Combination therapy using interleukin-2 and tumor necrosis factor |
US5425940A (en) * | 1986-04-09 | 1995-06-20 | Cetus Oncology Corporation | Combination therapy using interleukin-2 and tumor necrosis factor |
US4752479A (en) * | 1986-05-27 | 1988-06-21 | Ciba-Geigy Corporaton | Multi vitamin and mineral dietary supplement with controlled release bioavailable iron |
US5563126A (en) * | 1986-11-20 | 1996-10-08 | Metabolite Laboratories | Method for treatment and prevention of deficiencies of vitamins B12, folic acid, and B6 |
US5906816A (en) * | 1995-03-16 | 1999-05-25 | University Of Florida | Method for treatment of autoimmune diseases |
US5705363A (en) * | 1989-03-02 | 1998-01-06 | The Women's Research Institute | Recombinant production of human interferon τ polypeptides and nucleic acids |
US6372206B1 (en) * | 1989-03-02 | 2002-04-16 | University Of Florida | Orally-administered interferon-TAU compositions and methods |
ATE79763T1 (de) * | 1989-04-11 | 1992-09-15 | Boehringer Ingelheim Int | Verwendung von mindestens ein cytokin zur herstellung eines arzneimittels zur systemischen behandlung von praeneoplastischen laesionen. |
US5827513A (en) * | 1990-06-29 | 1998-10-27 | Schering Corporation | Methods of treating insulin-dependent diabetes mellitus by administration of IL-10 |
US5300292A (en) * | 1991-05-03 | 1994-04-05 | The Regents Of The University Of California | Composition and method for treating inflammation |
US5368854A (en) * | 1992-08-20 | 1994-11-29 | Schering Corporation | Use of IL-10 to treat inflammatory bowel disease |
US5880114A (en) * | 1993-06-16 | 1999-03-09 | Wisconsin Alumni Research Foundation | Treatment of immune deficiency with vitamin D compounds |
US6346243B1 (en) * | 1994-04-12 | 2002-02-12 | Research Development Foundation | Inhibition of transplant rejection by type one interferon |
US5632983A (en) * | 1994-11-17 | 1997-05-27 | University Of South Florida | Method for treating secondary immunodeficiency |
SE9600070D0 (sv) * | 1996-01-08 | 1996-01-08 | Astra Ab | New oral pharmaceutical dosage forms |
AU5689898A (en) * | 1996-12-05 | 1998-06-29 | University Of Florida | Il-10 and tgf-beta for treating autoimmune disease |
US6036949A (en) * | 1998-03-05 | 2000-03-14 | Amarillo Biosciences, Inc. | Treatment of fibromyalgia with low doses of interferon |
DE19843793C2 (de) * | 1998-09-24 | 2000-08-03 | Gruenenthal Gmbh | Substituierte Benzamide |
JP2000226335A (ja) * | 1998-12-04 | 2000-08-15 | Amano Pharmaceut Co Ltd | 経口用酵素製剤、酵素含有食材及び酵素製剤の服用方法 |
EP1114998A3 (de) * | 1999-10-28 | 2001-08-22 | Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno | Verfahren zur Bestimmung von Erfolgsquote von Multiple Sklerose-Behandlung |
US7083782B2 (en) * | 2000-07-19 | 2006-08-01 | Pepgen Corporation | Method of treatment using interferon-tau |
US7431920B2 (en) * | 2000-07-19 | 2008-10-07 | Pepgen Corporation | Method of treating IL-10 deficiency |
JP2006213597A (ja) * | 2000-07-19 | 2006-08-17 | Pepgen Corp | インターフェロン−タウを用いるc型肝炎ウイルスの処置のための組成物およびモニタリングの方法 |
US7105154B2 (en) * | 2000-07-19 | 2006-09-12 | Pepgen Corporation | Method of treatment using interferon-tau |
EP1355938A2 (de) * | 2000-07-19 | 2003-10-29 | Pepgen Corporation | Zusammensetzung zur behandlung von hepatitis c virus und verfahren zu dessen überwachung unter verwendung von interferon-tau |
US20040247565A1 (en) * | 2000-07-19 | 2004-12-09 | Chih-Ping Liu | Method of treatment using interferon-tau |
US7208167B2 (en) * | 2000-08-07 | 2007-04-24 | Sciclone Pharmaceuticals, Inc. | Treatment of hepatitis C with thymosin and peptide combination therapy |
GB0020089D0 (en) * | 2000-08-15 | 2000-10-04 | Smithkline Beecham Biolog | Vaccine Composition |
US20040013643A1 (en) * | 2000-09-19 | 2004-01-22 | Novlmmune S.A. | Methods for treatment of multiple sclerosis with statins |
US20040086508A1 (en) * | 2001-06-05 | 2004-05-06 | Advanced Biotherapy, Inc. | Treatment of organ transplant rejection |
JP2005506957A (ja) * | 2001-06-11 | 2005-03-10 | トランジション・セラピューティックス・インコーポレーテッド | ウイルス性、増殖性および炎症性の疾患の治療のためにビタミンb12およびインターフェロンを用いた複合治療 |
US20030017136A1 (en) * | 2001-07-17 | 2003-01-23 | Cruz Tony F. | Pharmaceutical compositions comprising vitamin B12 and interferon-beta for treating multiple sclerosis |
US7232563B2 (en) * | 2001-08-12 | 2007-06-19 | Pepgen Corporation | Hybrid interferon/interferon tau proteins, compositions and methods of use |
WO2003024461A1 (en) * | 2001-09-20 | 2003-03-27 | Schering Corporation | Hcv combination therapy |
EP1476191A2 (de) * | 2002-01-16 | 2004-11-17 | Pepgen Corporation | Orale verabreichung von interferon-tau |
US9034310B2 (en) * | 2002-02-21 | 2015-05-19 | Stephen B. Cantrell | Interferon-statin combination cancer therapy |
EP1494665A1 (de) * | 2002-03-29 | 2005-01-12 | The Board of Trustees of The Leland Stanford Junior University | Verwendung von statinen und anderen immunmodulatorischen mitteln zur behandlung von autoimmunkrankheiten |
WO2003099207A2 (en) * | 2002-05-24 | 2003-12-04 | Agennix Incorporated | Oral lactoferrin in the treatment of respiratory disorders |
TWI430810B (zh) * | 2002-07-19 | 2014-03-21 | Abbott Lab S A | TNFα相關病症之治療 |
US20050014734A1 (en) * | 2003-07-18 | 2005-01-20 | Genovate Biotechnology Co., Ltd. | Modulation of interleukin-10 by DHEA |
-
2005
- 2005-01-21 US US11/040,706 patent/US20050226845A1/en not_active Abandoned
- 2005-03-09 KR KR1020067019966A patent/KR20070004781A/ko not_active Application Discontinuation
- 2005-03-09 EP EP05734803A patent/EP1740201B1/de active Active
- 2005-03-09 CA CA002558803A patent/CA2558803A1/en not_active Abandoned
- 2005-03-09 WO PCT/US2005/007887 patent/WO2005087254A2/en active Application Filing
- 2005-03-09 AT AT05734803T patent/ATE413187T1/de not_active IP Right Cessation
- 2005-03-09 AU AU2005221682A patent/AU2005221682A1/en not_active Abandoned
- 2005-03-09 JP JP2007502983A patent/JP2007528407A/ja active Pending
- 2005-03-09 DE DE602005010844T patent/DE602005010844D1/de active Active
- 2005-03-10 CA CA002558645A patent/CA2558645A1/en not_active Abandoned
- 2005-03-10 WO PCT/US2005/008314 patent/WO2005087255A2/en active Application Filing
- 2005-03-10 AU AU2005221710A patent/AU2005221710A1/en not_active Abandoned
- 2005-03-10 KR KR1020067019967A patent/KR20070012801A/ko not_active Application Discontinuation
- 2005-03-10 EP EP05733251A patent/EP1730528A2/de not_active Withdrawn
- 2005-03-10 JP JP2007503082A patent/JP2007530452A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2005087254A3 (en) | 2006-02-02 |
US20050226845A1 (en) | 2005-10-13 |
WO2005087255A2 (en) | 2005-09-22 |
JP2007528407A (ja) | 2007-10-11 |
WO2005087255A3 (en) | 2006-04-20 |
EP1740201B1 (de) | 2008-11-05 |
CA2558645A1 (en) | 2005-09-22 |
AU2005221682A1 (en) | 2005-09-22 |
EP1740201A2 (de) | 2007-01-10 |
EP1730528A2 (de) | 2006-12-13 |
WO2005087254A2 (en) | 2005-09-22 |
KR20070012801A (ko) | 2007-01-29 |
KR20070004781A (ko) | 2007-01-09 |
JP2007530452A (ja) | 2007-11-01 |
ATE413187T1 (de) | 2008-11-15 |
CA2558803A1 (en) | 2005-09-22 |
AU2005221710A1 (en) | 2005-09-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1118849T1 (el) | Θεραπεια συνδυασμου για τη θεραπευτικη αγωγη διαταραχων ανεπαρκειας πρωτεϊνης | |
EE200200578A (et) | Antihüpertensiivsete ja antiangiogeensete ainete terapeutilised kombinatsioonid | |
NO20050807L (no) | Farmasoytiske sammensetninger som innbefatter dekstrometorfan og kinidin for behandling av neurologiske forstyrrelser | |
CY1121822T1 (el) | Βραδεια ενδοκοιλιακη χορηγηση | |
DE602005010844D1 (de) | Pharmazeutische zusammensetzungen mit interferon-tau | |
WO2006008639A8 (en) | Combination treatment for non-hematologic malignancies using an anti-igf-1r antibody | |
NO20062198L (no) | Bradykinin B1 reseptorantagonister | |
WO2006053049A3 (en) | Herbal composition phy906 and its use in chemotherapy | |
EA201270144A1 (ru) | Комбинированная терапия при лечении диабета | |
WO2006093784A3 (en) | Dosage forms of antibiotics and combinations of antibiotics ans symptomatic relief agents | |
WO2007062093A3 (en) | Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor | |
RS52867B (en) | GLATIRAMER ACETATOM AND RAZAGILIN COMBINED THERAPY FOR MULTIPLE SCLEROSIS | |
ATE494889T1 (de) | Pharmazeutische kombination mit 3- (3- dimethylamino-1-ethyl-2-methyl-propyl)-phenol und paracetamol | |
NO20071795L (no) | Octenidin-inneholdende tabletter anvendt mot betennelsessykdommer i munn og svelg | |
EE200200565A (et) | Vaskulaarse kahjustava toimega kombinatsioonravi | |
WO2007098106A3 (en) | Respiratory tract delivery of interferon-tau | |
DK1680128T3 (da) | Myo-inositolhexaphosphat til topisk anvendelse | |
LU92202I2 (fr) | Aflibercept | |
NO20075393L (no) | Akarbosebaserte fremgangsmater og utforminger for behandling av kronisk forstoppelse | |
NO20044498L (no) | Kombinasjonsterapi for behandling av cancer | |
NO20051261L (no) | Morfin-6-glukuronidsalt | |
MD2549F1 (en) | Method of treatment of the chronic viral hepatitis C | |
CY1112440T1 (el) | Απογλυκοζυλιωμενη και αποσιαλιδωμενη μακρα πεντραξινη ρτχ3 | |
AR045074A1 (es) | Uso de cd164 soluble en desordenes inflamatorios y autoinmunes | |
RU2007138266A (ru) | Комбинация ингибитора стероидсульфатазы и аскомицина |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |